SNIPR BIOME receives funding from the Bill & Melinda Gates Foundation to accelerate the development of SNIPR Biome's microbial gene therapy platform.
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients Phase 1b/2a trial will evaluate SNIPR001 for the...
Can CRISPR—a gene editing mechanism born from a bacterium’s antiviral system—be used as an antibiotic? That’s what SNIPR Biome wants to know, and new interim data from an early phase 1 study seem to show that a CRISPR-based therapeutic can in fact reduce levels of antibiotic resistant E. coli in humans.
Copenhagen, August 2nd, 2022: SNIPR Biome ApS (or “the Company”), a clinical-stage biotechnology company developing CRISPR-based precision medicines, announces today the grant of patent number US11,400,110 by the US Patent and Trademark Office (USPTO), further strengthening its intellectual property portfolio which now contains more than 20 granted patents in the USA and Europe for editing prokaryotes using CRISPR/Cas.
SNIPR BIOME ApS, a leading CRISPR and microbiome gene therapy biotechnology company, today announced dosing of the first human subjects in its phase...
COPENHAGEN, Denmark, March 8, 2022 /PRNewswire/ -- SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, is opening a 175 square meter state-of-the-art BSL2/GMO2-classified laboratory in Copenhagen. The new facilities will be among the largest GMO2 laboratories in Scandinavia and Northern Europe with the capacity to handle clinical samples from the phase 1 clinical trial with SNIPR001 and expand the company's CRISPR and microbiome portfolio.
COPENHAGEN, Denmark, Jan. 25, 2022 /PRNewswire/ -- SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for SNIPR001. SNIPR001 is the company's first development candidate targeting E. coli in patients with hematological malignancy at risk of neutropenia. This announcement comes only a few weeks after the FDA approved the Investigational New Drug (IND) Application paving the way initiating the first clinical trial in humans.